drugset / Trial / NCT00795717

Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

NCT00795717

Phase 4 Completed 41 enrolled Tufts University
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine whether fish oil supplementation with Lovaza, formally known as Omacor will result in a significant reduction in serum triglyceride (TG), an increase in high density lipoproteins(HDL), and an improvement of endothelial dysfunction.

Timeline

Start
2008-07
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lovaza Other / unclassified 4 g